Supplementary Table S1 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

Bruna Pellini; Russell William Madison; Merrida A. Childress; Shoshana T. Miller; Ole V. Gjoerup; Jason Cheng; Richard S.P. Huang; Michael R. Krainock; Pratyush Gupta; Wei Zou; David S. Shames; Solomon Moshkevich; Marcus Ballinger; MC Liu; Amanda G. Young; Minu K. Srivastava; Geoffrey R. Oxnard; Mark A. Socinski

doi:10.1158/1078-0432.31084993

Supplementary Table S1 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

2026 Open access

Read full text

Authors: Bruna Pellini, Russell William Madison, Merrida A. Childress, Shoshana T. Miller, Ole V. Gjoerup, Jason Cheng, Richard S.P. Huang, Michael R. Krainock, Pratyush Gupta, Wei Zou, David S. Shames, Solomon Moshkevich

+6 more

Marcus Ballinger, MC Liu, Amanda G. Young, Minu K. Srivastava, Geoffrey R. Oxnard, Mark A. Socinski

DOI: 10.1158/1078-0432.31084993

Cited by: 0

Abstract

Biomarker analysis patient cohort characteristics and ITT patient characteristics. Clinical and biomarker characteristics are similar between treatment arms of the biomarker analysis patient cohort evaluated in this study. Clinical and biomarker characteristics are similar between the ITT population in IMpower131 and the biomarker analysis patient cohort evaluated in this study.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics Lung Cancer Diagnosis and Treatment

Publication details

Publication date: 19 January 2026